Since DDR1 is the most prevalent target among synergistic drugs identified and is known to be highly elevated in tumors of the brain, we performed a parallel comparison of our selected gene panel for percent genomic alterations, relative mRNA expression, and transcriptional correlations in patient datasets of COAD, GBM, and Pan-Cancer Atlas (source, genomics portals: cBioPortal and GEPIA). The gene discussed is DDR1; the disease is brain neoplasm.